Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Microport Cardioflow Completes $324 Million HK IPO for Heart Valve Devices

publication date: Feb 16, 2021

Shanghai Microport Cardioflow Medtech, a spinout from China medical device maker Microport, completed a $324 million IPO in Hong Kong. Cardioflow develops transcatheter aortic valve implantation (TAVI) products that replace defective heart valves through a minimally invasive procedure. Its Vitaflow product, the first China TAVI device to use bovine pericardium as valve tissue, was approved for China use in 2019. The company is working on bringing Vitaflow to global markets. Cardioflow is trading 59% above its IPO price at a market capitalization of $6 billion. More details....

Stock Symbols: (HK: 2160) (HK: 0853)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.